Zobrazeno 1 - 10 of 12 pro vyhledávání: '"Bahar Matin"'
2
Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody Drug Conjugates to Increase In Vivo Efficacy
Autor: Christopher W. Espelin, Michael L. Miller, Richard J. Gregory, Ravi V. J. Chari, Thomas A. Keating, Leanne Lanieri, Jan Pinkas, Eshita Khera, Neeraj Kohli, Bahar Matin, Olga Ab, Yulius Setiady, Greg M. Thurber, Rassol Laleau, Jose F. Ponte
Publikováno v: Mol Cancer Ther
Several antibody–drug conjugates (ADC) showing strong clinical responses in solid tumors target high expression antigens (HER2, TROP2, Nectin-4, and folate receptor alpha/FRα). Highly expressed tumor antigens often have significant low-level expre
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d2e301f9d9125eef2ded1e3c0cffdd9
https://europepmc.org/articles/PMC7790875/
Zobrazit plný text záznamu
3
Resveratrol glucuronidation in vitro: potential implications of inhibition by probenecid
Autor: Bahar Matin, Ahmad A Sherbini, David J. Greenblatt, Jerold S. Harmatz, Novera Alam
Publikováno v: Journal of Pharmacy and Pharmacology. 71:371-378
Objectives Resveratrol is a naturally occurring antioxidant with therapeutic potential in prevention and treatment of neoplastic disease and other human disorders. However, net clearance of resveratrol in humans is very high, mainly due to glucuronid
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd209fc20fb38b425f22bdfe34a5143e
https://doi.org/10.1111/jphp.13037
Zobrazit plný text záznamu
4
Abstract B055: Phase 1b/2 study of rebastinib (DCC-2036) in combination with paclitaxel: Preliminary safety, efficacy, pharmacokinetics and pharmacodynamics in patients with advanced or metastatic solid tumors
Autor: Erika Hamilton, Filip Janku, Bahar Matin, Keisuke Kuida, Sanjay Goel, Michael J. Birrer, Debra L. Richardson, Christina Chu, Ying Su, Rodrigo Ruiz-Soto
Publikováno v: Molecular Cancer Therapeutics. 18:B055-B055
Background: Rebastinib is an orally administered, kinase inhibitor targeting the switch pocket of tunica interna endothelial cell kinase (TIE2). TIE2 is primarily expressed in endothelial cells, playing a role in angiogenesis. In addition, TIE2 is ex
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c6bb00dcc9b93b854f0d6d0775234aca
https://doi.org/10.1158/1535-7163.targ-19-b055
Zobrazit plný text záznamu
5
The impact of Megf10/Drpr gain-of-function on muscle development in Drosophila
Autor: Robert N. Salomon, Isabelle Draper, Peter B. Kang, Bahar Matin, Madhurima Saha, Hannah Stonebreaker
Publikováno v: FEBS letters. 593(7)
Recessive mutations in multiple epidermal growth factor-like domains 10 (MEGF10) underlie a rare congenital muscle disease known as MEGF10 myopathy. MEGF10 and its Drosophila homolog Draper (Drpr) are transmembrane receptors expressed in muscle and g
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34b4853845d6d8a2a4ac51dcf3b42cb6
https://pubmed.ncbi.nlm.nih.gov/30802937
Zobrazit plný text záznamu
6
Inhibition of 2-methoxyestradiol glucuronidation by probenecid
Autor: David J. Greenblatt, John J. Castellot, Yanli Zhao, Bahar Matin, Yuli Qian, Ahmad A Sherbini
Publikováno v: Journal of Pharmacy and Pharmacology. 67:1585-1592
Objectives 2-Methoxyestradiol (2ME2), a metabolite of estradiol, has antitumour activity in vitro. However, potential clinical applicability has been limited by low oral bioavailability. Probenecid was evaluated in vitro as an inhibitor of 2ME2 glucu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::407207053310cb696009509a0c292979
https://doi.org/10.1111/jphp.12462
Zobrazit plný text záznamu
9
Abstract 229: Utilizing a mouse cross-reactive model system to better understand antibody-drug conjugate pharmacokinetics, biodistribution and efficacy
Autor: Nicholas C. Yoder, Rassol Laleau, Bahar Matin, Steven Boule, Neeraj Kohli, Yulius Setiady, Jan Pinkas, Paulin Salomon, Richard Gregory, Leanne Lanieri, Michael L. Miller, Luke Harris, Thomas A. Keating, Jenny Lee
Publikováno v: Cancer Research. 79:229-229
Antibody-drug conjugates (ADCs) are designed to deliver a potent cytotoxic payload directly to tumors, thus limiting exposure in normal tissues. However, target antigen expression on normal tissues can lead to lower systemic ADC exposures, resulting
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::57ca65eb38f5edb9c6c87bee72449b6a
https://doi.org/10.1158/1538-7445.am2019-229
Zobrazit plný text záznamu
10
Abstract 3898: Preclinical evaluation of DM21, a next-generation maytansinoid payload with a stable peptide linker
Autor: Jan Pinkas, Wayne C. Widdison, Bahar Matin, Richard Gregory, Juliet Costoplus, Laura M. Bartle, Nicole McBrine, Olga Ab, Wayne Deats
Publikováno v: Cancer Research. 79:3898-3898
Antibody drug conjugates (ADCs) are designed to target surface antigen(s) expressed at higher levels on cancer cells compared to normal cells. ADCs are internalized and the antibody component is subsequently degraded in catabolic vesicles to release
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::995fd7ff3c50efc16caea042f7929d76
https://doi.org/10.1158/1538-7445.am2019-3898
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje